Canadian Cancer Trials Group Bulletins


Recent Publications

Canadian Cancer Trials Group MA.17L -- The Influence of Letrozole on Serum Lipid Concentrations in Women with Primary Breast Cancer Who Have Completed Five Years of Adjuvant Tamoxifen. A Companion Study to MA.17

Lipid Concentrations in Postmenopausal Women on Letrozole After 5 Years of Tamoxifen: An Canadian Cancer Trials Group MA.17 Sub-Study

MA.17L is a double-blind, placebo-controlled trial of extended adjuvant letrozole. The purpose of this study was to evaluate changes in serum lipid parameters (cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, and lipoprotein(a)) in postmenopausal women receiving letrozole after tamoxifen therapy.

Significant increases in total cholesterol, HDL cholesterol, LDL cholesterol, and, most notably, lipoprotein(a) in postmenopausal women were observed following 5 years of adjuvant letrozole treatment and after 5 years of tamoxifen therapy and the authors recommend that these patients should have monitoring of their lipid levels in clinical practice.

Wasan K, Goss P, Pritchard PH, Shepherd L, Tu D, Ingle JN. Lipid concentrations in postmenopausal women on letrozole after 5 years of tamoxifen: an Canadian Cancer Trials Group MA.17 sub-study (ONLINE). Breast Cancer Res Treat 1-8, 2012.

Canadian Cancer Trials Group HD.7 (ECOG 2496) -- A Randomized Phase III Trial of ABVD versus Stanford V with or without Radiation Therapy in Locally Extensive and Advanced Stage Hodgkin's Disease

Tumor-Associated Macrophages Predict Inferior Outcomes in Classic Hodgkin Lymphoma: A Correlative Study from the E2496 Intergroup Trial

Increased tumor-associated macrophages (TAMs) are reported to be associated with poor prognosis in classic Hodgkin lymphoma (CHL). The authors investigated the prognostic significance of TAMs in Canadian Cancer Trials Group HD.7 (ECOG 2496) and were able to demonstrate the prognostic significance of TAMs in locally extensive and advanced-stage CHL in a multicenter phase 3 randomized controlled clinical trial.

Tan KL, Scott DW, Hong F, Kahl BS, Fisher RI, Bartlett NL, Advani RH, Buckstein R, Rimsza LM, Connors JM, Steidl C, Gordon LI, Horning SJ, Gascoyne RD. Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial. Blood 120: 3280-7, 2012


Canadian Cancer Trials Group OV.17 (GINECO CALYPSO) -- A Multi-National, Randomized, Phase III, GCIG Intergroup Study Comparing Pegylated Liposomal Doxorubicin (Caelyx) and Carboplatin vs Paclitaxel and Carboplatin in Patients with Epithelial Ovarian Cancer in Late Relapse (> 6 months): GCIG CALYPSO Study

Canadian Cancer Trials Group OV.15 (AGO OVAR 2.5) -- International Randomized Phase III Study Comparing Gemcitabine plus Carboplatin versus Carboplatin Monotherapy in Patients with Advanced Epithelial Ovarian Carcinoma Who Failed First-Line Platinum-Based Therapy

A Prognostic Nomogram to Predict Overall Survival in Patients with Platinum-Sensitive Recurrent Ovarian Cancer

The nomogram was developed using data from Canadian Cancer Trials Group OV.17 (GINECO CALYPSO), and two simpler models with fewer variables were developed using data from two other trials, including Canadian Cancer Trials Group OV.15 (AGO-OVAR). This nomogram with six pre-treatment characteristics improves overall survival prediction in patients with platinum-sensitive ovarian cancer and is superior to models with fewer prognostic factors or platinum chemotherapy free interval alone. The authors suggest that with independent validation, this nomogram could potentially be useful for improved stratification of patients in clinical trials and also for counselling patients.

Lee CK, Simes RJ, Brown C, Gebski V, Pfisterer J, Swart AM, Berton-Rigaud D, Plante M, Skeie-Jensen T, Vergote I, Schauer C, Pisano C, Parma G, Baumann K, Le Kurzeder C, Friedlander M. A prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancer (ONLINE). Ann Oncol 2012.